Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jun 06, 2022 10:45pm
194 Views
Post# 34735926

RE:Warrant's

RE:Warrant's
Doccole wrote: This is coming due, will it have any effect on the stock price?

Each Unit was comprised of one common share of the Company (a "
Common Share") and one-third of one common share purchase warrant. Each full warrant is exercisable to purchase one Common Share at any time prior to June 30, 2022 at a price of $0.60 per Common Share.


Correct ...

June 20 - I'm assuming about 3M warrants set to expire ($6)
Aug 13 - 1.3M warrants may expire ($4)
Feb 24, 2024 - 3M warrants to wonder about ($7.50)

---------------------

We won't have the dilution of shares but we also won't get the cash that comes in to buy the part shares.  I'd say no effect on the price based on this event alone.

But - June 30th is a world away.
Do we get Q4 financials before then or by end of July - guessing end of June.
Do we get an update by then or not ?  TBD
Price could move for other reasons - likely not for expiring warrants.




<< Previous
Bullboard Posts
Next >>